Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Enterprise Value (2021 - 2025)

Roivant Sciences' Enterprise Value history spans 5 years, with the latest figure at -$3.8 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 31.52% year-over-year to -$3.8 billion; the TTM value through Dec 2025 reached -$3.8 billion, down 31.52%, while the annual FY2025 figure was -$4.4 billion, 27.06% up from the prior year.
  • Enterprise Value reached -$3.8 billion in Q4 2025 per ROIV's latest filing, up from -$3.9 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.0 billion in Q2 2023 to a low of -$6.2 billion in Q4 2023.
  • Average Enterprise Value over 5 years is -$2.9 billion, with a median of -$2.2 billion recorded in 2021.
  • Peak YoY movement for Enterprise Value: tumbled 487.71% in 2023, then surged 53.13% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$2.2 billion in 2021, then skyrocketed by 51.89% to -$1.1 billion in 2022, then crashed by 487.71% to -$6.2 billion in 2023, then soared by 53.13% to -$2.9 billion in 2024, then tumbled by 31.52% to -$3.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Enterprise Value are -$3.8 billion (Q4 2025), -$3.9 billion (Q3 2025), and -$2.9 billion (Q2 2025).